New imaging agent hopes to spot prostate cancer spread

NCT ID NCT07162779

ENROLLING_BY_INVITATION Diagnosis Sponsor: Affiliated Hospital of Jiangnan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early study tests a new radioactive tracer called [68Ga]DOTA-IR-780-C-4 for PET/CT imaging in men with PSMA-positive prostate cancer. The goal is to see if it can accurately detect primary and metastatic lesions. Only 5 participants are enrolled, and they will receive the tracer intravenously followed by scans at 1, 2, and 3 hours. This is a diagnostic trial, not a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [68Ga]DOTA-IR-780-C-4 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could provide a new imaging tool to help doctors find prostate cancer spread more accurately.
What could go wrong: This is a very early, tiny study with only 5 people. It only tests imaging, not treatment, and may not lead to any change in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PET/CT

Contacts and locations

Locations

Jiangnan University Affiliated Hospital

Wuxi, Jiangsu, 214026, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.